Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.…
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
Codexis (NASDAQ: CDXS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 146 employees.
The shares were at 1.010 USD on 20 November 2026, down 40.2% over 52 weeks. Its 52-week range is 0.9000 USD to 2.980 USD: the price is 66.1% below the high and 12.2% above the low.
Its market capitalisation is 110.69M USD.
Codexis reports return on equity of -87.0%, an operating margin of -14.4% and revenue up 124.0% year over year.
It holds more cash than debt, a net cash position of 392.00K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 10 March 2027.